Meri Rogava

Potentiating Natural Killer Cell-mediated Cytotoxicity in Medulloblastoma 2308814

Anjali Rachelkar, Alon Kashanian, Steven Schneider, Rachel Pruitt et autres

Abstract Introduction Medulloblastoma (MB) is the most common malignant pediatric brain tumor and comprises four molecular subgroups (WNT, SHH, Group 3, Group 4). Although generally presenting an immunologically “cold” tumor microenvironment, flow cytometric (FC) profiling of primary tumor samples from our laboratory …

us, de (code pays fourni par la source)

Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis

Charlie Chung, Elif Ozcelik, J Zhang, Zeli Shen et autres

Colorectal cancer remains a major cause of cancer mortality, and most microsatellite stable tumors derive little benefit from immune checkpoint blockade. Here, we identify a microbiome-dependent mechanism that converts immune-refractory colorectal cancer into a more immunologically responsive state. Using orthotopic mouse models …

us (code pays fourni par la source)

362 Dissecting immune evasion in pediatric brain tumors through organoid models and multiplex immune profiling

Meri Rogava, Zarina Brune, Anjali Rachelkar, Rachel Pruitt et autres

Background Pediatric brain tumors (PBTs), including medulloblastoma and H3K27M-mutant diffuse midline gliomas, remain the most lethal childhood cancers and exhibit limited responsiveness to current immunotherapies. As a young investigator committed to developing precision immunotherapy strategies for pediatric patients, I aim to characterize …

us, fr (code pays fourni par la source)

Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases

Lindsay Caprio, Amit Dipak Amin, Kresimir Bestak, Karan D. Luthria et autres

us, de (code pays fourni par la source)

Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma

Trang Thi Thu Nguyen, Qiuqiang Gao, Jeong-Yeon Mun, Zhe Zhu et autres

Immunotherapies have shown significant promise as an impactful strategy in cancer treatment. However, in glioblastoma multiforme (GBM), the most prevalent primary brain tumor in adults, these therapies have demonstrated lower efficacy than initially anticipated. Consequently, there is an urgent need for strategies …

us, de (code pays fourni par la source)

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens

Zachary H. Walsh, Parin Shah, Neeharika Kothapalli, Shivem B. Shah et autres

us (code pays fourni par la source)

Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors

Christy Hong, Lindsay Caprio, Mercedes A. Duran Paez, Meri Rogava et autres

Abstract The activation of STING (stimulator of interferon genes) has been widely shown to induce signaling pathways, triggering type I interferon and ultimately generating anti-tumor immunity. Whereas initial preclinical studies on STING agonists exhibited boost in anti-tumor response, clinical trials combining STING …

us (code pays fourni par la source)

Abstract 5360: Relief of chromosomal instability-induced cGAS-STING signaling sensitizes STK11-mutant non-small cell lung cancer to immune checkpoint blockade

Lindsay Caprio, Christy Hong, Amit Dipak Amin, Somnath Tagore et autres

Abstract Non-small cell lung cancers (NSCLCs) harboring deletions or inactivating mutations in STK11 (encoding LKB1) are associated with poor prognosis and immune evasion, but the underlying mechanisms are poorly understood. Through integrative analyses of >10,000 molecular profiles from public data sources and …

us (code pays fourni par la source)

Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation

Meri Rogava, Tyler J. Aprati, Wei-Yu Chi, Johannes C. Melms et autres

us, de (code pays fourni par la source)

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Nasser Khaled Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port et autres

In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

us, il (code pays fourni par la source)

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Nasser Khaled Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port et autres

We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic …

us, il (code pays fourni par la source)

From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6

Johannes C. Melms, Patricia L. Ho, Meri Rogava, Benjamin Izar

us (code pays fourni par la source)